Medscape4d
Osimertinib OS Benefit Persists Among Patients With EGFR+ NSCLC
OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...
CURE3d
Tagrisso May Improve Survival in Advanced EGFR-Mutant NSCLC
Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer ...
Morningstar10d
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
In the 80 TAGRISSO-treated patients ... during treatment with TAGRISSO and for 2 weeks after the last dose While EGFR-TKIs have significantly improved outcomes in the 1st-line setting, mechanisms ...
Medscape5d
Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine
Objective Many societies recommend using estimated glomerular filtration rate (eGFR) rather than serum creatinine (sCr) to determine metformin eligibility. We examined the potential impact of ...
PharmExec9d
Updated Trial Results Support Tagrisso as Standard-of-Care for EGFR-Mutated Lung Cancer
Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung ...